The peptides getting the most attention right now GLP-1 agonists like semaglutide (Ozempic, Wegovy) mimic a gut hormone that regulates appetite and blood sugar
Nevertheless, notable opportunities exist as well, especially in proliferating the utilization of GLP-1 RAs beyond diabetes treatment, and into application segments such as cardiovascular associated disorders and weight management
weekly), and personal preferencessuch as injection versus oral medication
Most cases of semaglutide not working are actually dosing or titration issues Nearly half of GLP-1 patients stop at 180 days due to side effects (52%), supply issues (33%), and cost (25%) A 2025 study found patients seeing an obesity specialist were 8 times more likely to stick with GLP-1s Rivas Medical Weight Loss has been treating obesity since 1991
2015 Apr;158(6):726-8
Obtain comprehensive baseline labs: TSH, free T4, free T3 Thyroid antibodies (TPO and thyroglobulin if not previously checked) Complete metabolic panel HbA1c and fasting glucose Lipid panel Vitamin D and B12 (commonly deficient in hypothyroidism) During Treatment When to Contact Your Provider Reach out if you experience: Unusual or worsening fatigue not explained by semaglutide initiation New or returning brain fog or cognitive difficulty Constipation that does not improve with typical measures Heart rate changes (especially sustained bradycardia) Cold intolerance or dry skin changes Weight loss plateau despite medication adherence Hair loss beyond what is expected with weight loss Mood changes including depression or anxiety Semaglutide Alternatives for Hypothyroid Patients For patients who cannot take semaglutide or prefer alternatives, several options exist: Tirzepatide (Mounjaro/Zepbound): Dual GLP-1/GIP agonist with potentially greater weight loss